Non-invasive transferrin targeted nanovesicles sensitize resistant glioblastoma multiforme tumors and improve survival in orthotopic mouse models
Puja Sandbhor, Jayant Sastri Goda, Bhabani Mohanty, Pradip Chaudhari, Shilpee Dutt, Rinti Banerjee
Abstract
Tc labeled LNs showed 500- and 280-fold increased brain concentration post 18 h of treatment. The efficacy of the TLNs increased by 1.8-fold in terms of survival of tumor-bearing mice compared to free drugs. These findings suggested that targeted drug synergy has the potential to intranasally deliver a high therapeutic dose of the chemotherapy agent (TMZ) and could serve as a platform for future clinical application.
Topics & Concepts
TemozolomideDrug deliveryGliomaPharmacologyBlood–brain barrierIn vivoBioavailabilityCancer researchMedicineBrain tumorDacarbazineDrugTransferrinNasal administrationParenchymaTargeted drug deliveryChemistryPathologyInternal medicineBiologyMelanomaCentral nervous systemBiotechnologyOrganic chemistryGlioma Diagnosis and TreatmentRNA Interference and Gene DeliveryNanoplatforms for cancer theranostics